Clinical Development of Concizumab, a Monoclonal Antibody for Subcutaneous Prophylaxis for all Hemophilia Patients

Time: 9:30 am
day: Day One

Details:

  • Assessment and discussion of Concizumab phase II data
  • Treatment that improve clinical outcomes and improve quality of life
  • Future development plans

Speakers: